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Review criteria
With the growing interest in deep brain stimulation (DBS) and its worldwide use, the leadership of the World Society for Stereotactic
and Functional Neurosurgery (WSSFN) decided to address the manifold unanswered questions and unmet needs in this rapidly
expanding field. To achieve this goal, the WSSFN produced this Review to outline the contemporary discussions, the challenges and
the future directions in this area on the basis of a dedicated workshop, which was held 9–11 March 2017. The objective of the
workshop was to identify the most pressing current and emerging challenges and unmet needs in the DBS field. Participants from
different disciplines were chosen on the basis of their special expertise in neuroscience, neurology, neurosurgery or psychiatry.
Specific sections were assigned to two experts, respectively, and the assembled text was then discussed by the whole group during an
intensive 2.5-day workshop. Discussion centred around several key topics, including the current clinical status of DBS, the role of
preclinical models, emerging science surrounding DBS mechanisms and the role of DBS in motor and non-motor conditions.
Additional topics included the ethical challenges surrounding the application of DBS in neurology and psychiatry as well as emerging
trends and future directions of the field. The manuscript then underwent several modifications over the next few months until
consensus with regard to both relevance and content was reached among the authors.
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Abstract
The clinical use of deep brain stimulation (DBS) is among the most important advances in the
clinical neurosciences in the past two decades. As a surgical tool, DBS can directly measure
pathological brain activity and can deliver adjustable stimulation for therapeutic effect in
neurological and psychiatric disorders correlated with dysfunctional circuitry. The development of
DBS has opened new opportunities to access and interrogate malfunctioning brain circuits and to
test the therapeutic potential of regulating the output of these circuits in a broad range of disorders.
Despite the success and rapid adoption of DBS, crucial questions remain, including which brain
areas should be targeted and in which patients. This Review considers how DBS has facilitated
advances in our understanding of how circuit malfunction can lead to brain disorders and outlines
the key unmet challenges and future directions in the DBS field. Determining the next steps in
DBS science will help to define the future role of this technology in the development of novel
therapeutics for the most challenging disorders affecting the human brain.
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The use of deep brain stimulation (DBS) to intervene directly in pathological neural circuits
has changed the way that brain disorders are treated and understood. DBS is a neurosurgical
procedure that involves the implantation of electrodes into specific targets within the brain
and the delivery of constant or intermittent electricity from an implanted battery source.
Over 160,000 patients worldwide have undergone DBS for a variety of neurological and
non-neurological conditions, with numbers increasing each year1. As a clinical tool, DBS
offers several advantages over other surgical approaches for neuromodulation. These
advantages include the non-lesional nature of DBS, the capacity to titrate stimulation
parameters to maximize benefit and reduce adverse effects and the opportunity to directly
interface with the circuit pathology that drives overt symptoms. As a scientific tool, DBS can
be used to investigate the physiological underpinnings of brain dysfunction, which enables
identification and correction of pathological neuronal signatures and helps to drive
technological innovation and enhance safety and clinical outcomes2. Furthermore, as a
highly focal intervention with anatomic targets typically on the order of millimetres, DBS
has contributed to circuit theories of brain dysfunction by demonstrating that localized
dysfunction and intervention can have profound influences on brain-wide networks3–5. This
duality of DBS as probe and modulator of brain circuitry has led to the investigation of the
therapeutic potential of DBS in a broad range of disorders, including those affecting motor,
limbic, memory and cognitive functions1. Notwithstanding its advantages, DBS remains an
invasive surgical intervention with low but potentially serious attendant risks, including
haemorrhage and infection. Although DBS has become standard of care in patients with
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movement disorders, its use in other disorders is limited to highly refractory patients and
conditions, typically in the context of expert multidisciplinary care and clinical research6.

Europe PMC Funders Author Manuscripts

To date, few indications have been approved for DBS, with the vast majority of procedures
performed for movement disorders, most commonly Parkinson disease (PD). Indeed, several
randomized controlled trials have found that few treatments are as effective as DBS for
controlling the troubling motor symptoms of PD7,8. However, despite the success of DBS,
PD is paradigmatic of both the promise and challenges of the technique. For example,
although DBS is highly effective in properly selected patients with PD, stimulation at the
most commonly used targets — the subthalamic nucleus (STN) or globus pallidus internus
(GPi) — is ineffective for the treatment of gait and other axial symptoms and does little to
improve (or can even exacerbate) speech and affective and cognitive symptoms9,10.
Therefore, intervention at a highly focal point is insufficient as a means of addressing
dysfunction of multiple circuits. This concept represents an important limitation and
challenge for the field. Additional technical and clinical challenges also exist. Technical
innovation will focus on the improvement of practicability, including extension of battery
life, design of smaller devices and development of more tailored and adaptive stimulation in
addition to the integration of wireless technology. Clinically, the main challenge will be to
meet the needs of an ageing population worldwide and expand indications for DBS to
circuitopathies other than PD, including depression and Alzheimer disease (AD)1. Even
within established indications such as PD, key questions remain unanswered. Biomarkers
that predict clinical response and aid in patient selection and stimulation parameter settings
are still largely lacking. Furthermore, the timing of intervention is controversial, with some
strong evidence that early surgery might be more beneficial than late7. Answers to these
questions will shape not only which patients are offered surgery but also the direction of the
field for years to come.
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The scope of DBS is rapidly expanding and parallels our increasing understanding of the
nature of brain circuit dysfunction (Table 1). In order to take stock of the field, this Review
addresses the status of DBS by highlighting its current challenges and future. We begin by
reviewing the putative mechanisms of DBS and its effects on neural tissue and networks,
followed by an overview of how preclinical models have informed translational applications.
We then provide an overview of the spectrum of clinical applications, from motor to nonmotor, including the challenges for both widely used and emerging indications. Finally, we
conclude by examining the clinical, technical and ethical challenges that will help to inform
future directions of the field.

Rationale and mechanisms of action
Many hypotheses have been proposed for the mechanisms by which DBS operates (Table 2).
Prevailing theories have focused on stimulation-induced disruption of pathological brain
circuit activity1,11. The stimulation effects responsible for this disruption occur at the ionic,
protein, cellular and network levels to generate improvements in symptoms12 (Fig. 1).
Although it is currently unclear which of the wide-ranging effects of DBS are necessary and
sufficient to generate therapeutic outcomes, it is clear that high-frequency (~100 Hz) trains

Nat Rev Neurol. Author manuscript; available in PMC 2019 March 02.

Lozano et al.

Page 4

of pulses (~0.1 ms) produce network responses that are fundamentally different (for
example, inhibitory effects) from low-frequency (~10 Hz) stimulation.
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At the ionic level, the purpose of an electrode implanted into the brain and polarized to a
negative potential (that is, a cathode) is to redistribute charged particles (such as Na+ and Cl−
ions) throughout the extracellular space. This redistribution creates an electric field that can
manipulate the voltage sensor of sodium channel proteins imbedded in the membrane of
neurons13. At the cellular level, the opening of sodium channels can generate an action
potential, which typically initiates in the axon. Stimulation-induced action potentials then
propagate in both the orthodromic and antidromic directions to the axon terminals of the
neuron. Under the typical conditions of DBS, many axons will be stimulated. The stimulated
axons are capable of following stimulation frequencies at ~100 Hz with very high fidelity,
but synaptic transmission of these high-frequency signals is a far less robust and much more
complicated process than that of axonal transmission14,15. Axon terminals can exhaust their
readily releasable pool of neurotransmitters and postsynaptic receptors can depress under
such high-frequency activity16,17. Even if these synapses remain functional during DBS,
information processing theories dictate that they will become low-pass filters that suppress
transmission of low-frequency signals18. This general phenomenon, known as ‘synaptic
filtering’, could have a key role in DBS, whereby the neurons and connections that are
directly stimulated by DBS hinder the propagation of oscillatory activity patterns within
their associated brain networks19.
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The basic biophysical effects of DBS provide a context in which to begin to interpret the
network activity patterns that are observed in patients. As stimulation frequency remains
constant during DBS, the information content of the stimulation signal is effectively zero,
which could generate what is known as an ‘information lesion’ in stimulated neurons20.
Under this hypothesis, DBS-induced action potentials effectively override any intrinsic
activity in the directly stimulated neurons and thereby limit the propagation of oscillatory
activity through the network. In addition, the basic concepts of information lesion and
synaptic filtering might work in concert to generate robust suppression of low-frequency
signals in stimulated brain circuits.
However, not all data support the hypothesis that high-frequency DBS introduces a simple
information lesion. Studies in awake and behaving primates have provided some evidence
that physiological sensorimotor-related discharge in the pallidum might be maintained at
least partially during STN or pallidal DBS21,22. These studies suggest that DBS might act
as a filter that permits some sensorimotor-related modulation of the activity of neurons in the
stimulated area while selectively blocking transmission of pathological low-frequency
oscillations. Likewise, other basal ganglia functions such as motor sequence learning or
reward-based decision-making can be preserved during DBS of the STN or globus
pallidus23. Nevertheless, the information lesion hypothesis might be reconciled with these
observations if physiological coding in the basal ganglia is predominantly supported by
mechanisms other than synchronization, which are thereby mostly spared by high-frequency
DBS. Indeed, the sparsity of correlations between neurons in the basal ganglia in health
supports this model24.
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Other network-level factors might also have important roles in the therapeutic mechanisms
of DBS for PD. First, the thalamus might act as a low-pass filter by transmitting
synchronized inputs from the basal ganglia at frequencies within and below the beta band
(12–30 Hz) but not transmitting signals at the high frequencies driven by DBS (>100 Hz)25–
28. Second, changes to circuit resonances in PD might maximize the potential for
postsynaptic targets to be entrained by low-frequency activity as opposed to the high
frequencies driven by DBS29,30. The net result of such factors is that high-frequency DBS
might provide an effective local information lesion that blocks the transmission of lowfrequency oscillations but, unlike synchronization at low frequency, might have little effect
on the function of the wider network27,31. One of the attractions of this schema is that highfrequency DBS then becomes a generic tool that is able to override different forms of
pathological low-frequency oscillation, such as those underlying mobile dystonia, tremor
and akinesia–rigidity32.
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The hypothetical mechanism for DBS outlined above helps to explain only the acute effects
of DBS in a subset of movement disorders. It does not explain the longlatency, chronic
adaptive changes that occur after DBS in patients with dystonia and can characterize the
response to DBS in psychiatric diseases such as depression. One relevant possibility is that
low-frequency oscillations are actively reinforced through long-term potentiation, whereas
high-frequency stimulation has a lesser effect on plasticity. In this way, replacement of lowfrequency patterning with high-frequency stimulation might undo some chronic diseaserelated phenomena33. Even so, little evidence currently supports an association between
psychiatric diseases and pathologically synchronized low-frequency activity within basal
ganglia–cortical circuits, which leaves open the possibility that DBS might also work
through other mechanisms. One key area of current interest is the effects of DBS on
astrocytes, given their role in integrating synaptic information and regulating synaptic
plasticity12. The effects of DBS are often delayed and progressive and sometimes take
months to achieve maximal benefit in a variety of disorders, including dystonia, depression
and epilepsy. Interest is growing in the neuroplastic changes induced by DBS that might be
linked to the ability to upregulate the expression of trophic and synaptic proteins with
stimulation34.

Insights from animal models
Animal models have played a crucial part in the clinical application of modern DBS in
patients with neurological disorders (Table 3). The most evident example is DBS of the STN
in PD. The STN was found to have an abnormally increased activity in non-human primates
with parkinsonian symptoms caused by treatment with 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP; an agent toxic to dopaminergic neurons in the STN)35.
However, experimental lesions of the STN resulted in clear-cut improvements of rigidity and
hypokinesia in the same animal model36,37. Lesions of the STN were so effective at
alleviating symptoms that levodopa or apomorphine therapy was not necessary. These
findings supported the hypothesis that pathological activity occurs in the STN in PD and that
ablation of this area would improve parkinsonian symptoms. In the meantime, DBSmediated blockage of depolarization, induced by chronic electrical stimulations at high
frequencies, was introduced as an alternative for ablation38. The final piece of evidence
Nat Rev Neurol. Author manuscript; available in PMC 2019 March 02.
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came again from an animal study. In monkeys rendered parkinsonian by MPTP, highfrequency stimulation of the STN improved motor disability. From these findings, a
successful therapy for patients with PD was born39.
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Another contribution of animal models to clinical application of DBS has been in the field of
epilepsy. In a guinea pig model of epilepsy, sectioning of the mammillothalamic tract
(MMT) increased the dose threshold for pharmacologically induced seizures40. The MMT
is a key component of the circuit of Papez and projects mainly to the anterior nucleus of the
thalamus (ANT). In animal models, electrical stimulation of the MMT or the ANT showed
anti-epileptic effects41,42. These findings, together with clinical case studies, were the basis
for the randomized controlled trial of DBS of the ANT in epilepsy43. This trial helped to
provide evidence for the efficacy of DBS in epilepsy. The search for effective targets for
DBS in specific types of epilepsy is ongoing44.
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In the field of psychiatric disorders, animal models have provided important insights into the
mechanisms of action of DBS45. Although early case series showed promising effects of
DBS in patients with treatmentrefractory depression, the outcomes of large controlled
clinical trials showed limited success46. Data from animal models provided new clues on
the potential cause of this discrepancy. DBS has been applied to a number of brain areas in
rats exposed to chronic mild stress, and the effects have been evaluated using a battery of
behavioural tests encoding motivation, anxiety, anhedonia and behavioural despair47. The
regions stimulated have a crucial role in the regulation of negative emotions and are
interconnected with a wide range of networks that form a neurocircuitry for affective
disorders48,49. The main conclusion of these studies was that different brain regions
improve different aspects of mood-related behaviours. High-frequency stimulation of the
nucleus accumbens and lateral habenula enhanced motivational aspects of behaviour and
reduced anxiety levels, whereas high-frequency stimulation of the ventromedial prefrontal
cortex enhanced hedonia and reduced behavioural despair47. These findings suggest that the
choice of brain target for DBS should depend on the key symptoms to be treated rather than
aiming to resolve a complex and multifaceted disorder such as depression. This approach
was demonstrated by one study that looked for potential targets for DBS to treat tics in
Tourette syndrome. Stimulation of the anteromedial part of the STN in monkeys that
exhibited tic-like behaviour resulted in a reduction of stereotyped movements in these
animals50.
Animal studies have also contributed substantially to our understanding of the mechanisms
underlying therapeutic and adverse effects of DBS. From an anatomical point of view, we
have learned that the effects of high-frequency stimulation go beyond the classic concepts of
monosynaptic connectivity. In dopamine-depleted rats, high-frequency stimulation of the
STN ameliorated motor disability but induced a remarkable change in mood. This effect was
linked to reduced firing of serotoninergic neurons in the midbrain51,52. These brain regions
are not connected directly, but high-frequency stimulation nevertheless uncovered a high
level of functional connectivity. Furthermore, electrical stimulation approaches have
demonstrated that individual STN neurons receive input from motor and limbic areas53. In
this way, two distinct behavioural modalities, motion and emotion, can converge, which
explains some of the mixed clinical effects of DBS.
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Among the major lessons learned from DBS in animal models is the differential effect of the
modulation of microcircuits and macrocircuits on key symptoms. This difference also
supports current shifts from modelling a disorder towards modelling key symptoms and
linking them to specific circuits and neuronal populations or subsets of these circuits and
populations. The availability of an increasing number of neuromodulation approaches for
animal models — involving electricity, light, sonography and magnetic nanoparticles — is
promising and is likely to facilitate new breakthroughs in the field of clinical DBS54.

DBS in movement disorders
Over the past 25 years, DBS has become the standard of care for patients with treatmentrefractory motor circuit disorders — most commonly PD, dystonia and essential tremor.
DBS is highly effective at controlling motor symptoms but remains very resource intensive.
To date, use of DBS has been limited to high-income countries, although use in many
developing nations is rising55. Analysis of a US database of hospital discharges between
2002 and 2011 showed that more than 30,000 DBS surgeries were performed during that
time56. The numbers of publications on DBS have also risen steeply over the same period,
with more than 7,000 manuscripts published between 1991 and 2014 (REF.57). A drop in
the number of publications in DBS for PD over the past 5 years might represent progressive
scholarly acceptance, whereby the number of investigations that refine or improve a
procedure eclipses the total number of reports assessing initial efficacy58.
Parkinson disease
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The STN, a key motor relay structure for which dysfunction has been linked to PD
symptoms, is the most commonly used target for DBS over the past 10 years59. The GPi is
also a common target, and the choice between the STN and GPi is most commonly informed
by discussion within a multidisciplinary team and dictated by the patient’s clinical profile
and needs. Although randomized studies have shown that STN stimulation might have a
greater effect on motor symptoms and dopaminergic medication reduction than GPi
stimulation, adverse cognitive and mood effects might be more common after STN
stimulation8,60. Numerous studies have also shown that STN DBS provides persistent
symptom improvement even 5 or 10 years after surgery, albeit with deterioration of
cognition and gait due to the relentless progression of the underlying degenerative
disorder61. DBS has been termed ‘the second honeymoon’ in the treatment of PD (with
dopaminergic treatment being the first). However, chronic DBS has also created a new
phenotype of PD: patients in whom bradykinesia, tremor, rigidity, on–off fluctuations and
dyskinesias are improved but who continue to present with progressive gait, speech and
cognition problems62. Gait problems, in particular, become important and difficult to
manage at late stages of the disease63. DBS of the pedunculopontine nucleus area has been
proposed as a measure to improve freezing and postural instability with the goal to reduce
related falls, but the selection of appropriate candidates and the difficulty of demonstrating
objective benefit have become major obstacles to widespread use of this approach64.
There is a general consensus that a particular type of patient with PD would benefit from
DBS — those with advanced disease, motor fluctuations and dyskinesias secondary to
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chronic levodopa as well as those with refractory and marked tremor. However, findings by
the EARLYSTIM study, which suggest that DBS at earlier stages of PD is associated with
substantial clinical benefit, have considerably widened the spectrum of patients with PD to
whom DBS is offered7. Indeed, trials have now begun to investigate the use of DBS even in
patients who do not have motor fluctuations and who can be managed well with
medication65. However, given the risk of haemorrhage and infection inherent with DBS,
such studies can pose ethical challenges. Ongoing work is now investigating the role of DBS
in other challenging cases, including in patients with PD who might be considered too old
for surgery — a population that is typically excluded from trials and other surgical
interventions66.
Dystonia
The development of DBS for dystonia has lagged about a decade behind its use in PD67.
Several randomized sham-controlled trials with blinded delayed-onset stimulation have now
demonstrated the efficacy of pallidal DBS for generalized and segmental primary (inherited
and idiopathic) dystonia and for cervical dystonia. As a result, DBS has come to play an
important part in the treatment of dystonic disorders68,69. For example, pallidal DBS is now
considered to be first-line treatment in some childhood generalized dystonias. Age at surgery
and duration of dystonia have been identified to be the most important outcome
predictors70–72. Genetic background has also been noted to have a major role; for example,
the benefit might be superior in patients with DYT1 dystonia compared with those with
DYT6 dystonia73. As a result, genetic testing of patients with dystonia who might undergo
DBS has been suggested to identify patients who are the most likely to benefit from the
procedure74.
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The posteroventral lateral GPi has become the most established target for DBS in
dystonia75. GPi stimulation provides marked improvement in many manifestations of
dystonia with a low frequency of adverse effects. However, bradykinesia and gait problems
have been found in patients (especially adults) with segmental dystonia who achieve a good
response to DBS; this phenomenon has not yet been fully understood, but it has opened new
views on the function of the basal ganglia76,77. Fortunately, these adverse effects usually
can be managed by making a compromise between maximal stimulation benefit and the
occurrence of these symptoms. Additional targets for DBS that are under investigation for
dystonia include the STN and the thalamus. However, despite promising preliminary results
of STN DBS, its clinical use thus far has been limited78. Another interesting target is the
sensorimotor thalamus, which was regarded as the standard target for dystonia in the era of
radiofrequency lesioning79,80. One challenge for future research will be to determine which
region in the ventrolateral thalamus would be the ideal target for DBS — the anterior (that
is, the Voa according to Hassler), posterior (the Vim) or intermediate regions (the region
formerly termed Vop).
The mechanisms by which DBS achieves its clinical effect in dystonia are complex, as
demonstrated by the often delayed and progressive improvement exhibited by patients over a
period of months. Hypotheses regarding the underlying mechanism include modification of
maladaptive plasticity, progressive motor learning, altered inhibition and alterations in
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pathological oscillatory activity in basal ganglia circuitry81. The long-term benefit of
chronic DBS in dystonia is often delayed, requiring weeks or months of stimulation to
achieve optimal benefit. Long-term stimulation also seems to produce long-lasting changes
in the brain. Interestingly, although dystonia can recur within minutes to hours after
stimulation has been turned off in the early postoperative period82, the benefits from
stimulation that has been administered for several years can persist for days and weeks after
cessation83. DBS might, therefore, act as a true disease-modifying treatment in dystonia,
which might justify its use earlier in the course of the disease and not just when conservative
treatment either is not available or is poorly effective. Such reasoning has prompted calls for
an EARLYSTIM study in dystonia. An unresolved issue is the limited benefit of DBS in
acquired forms of dystonia and in patients in whom dystonia is accompanied by other
neurological symptoms84. In particular, in this large group of patients, future outcome
evaluations need to move beyond the measurement of improvements solely with specific
scales that focus on the severity of dystonia. Patient-specific characteristics, such as baseline
functional status, need to be considered in addition to changes in disability and quality of
life, and the so-called success or failure of therapy in severely disabled patients might need
to be redefined85,86.
Tremor
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Essential tremor was the first movement disorder indication for which DBS was approved by
the FDA in 1997 (REF.38), and, after its efficacy was proved in numerous studies, it has
become a routine treatment87. Habituation and the emergence of long-term adverse effects
such as dysarthria and gait ataxia in a subset of patients after several years of chronic
stimulation remain challenges in DBS treatment of patients with essential tremor88.
Whether stimulation of the subthalamic region or direct targeting of fibre tracts in that area
would provide better long-term improvement is still unclear. Although DBS is safe and
effective, lesional therapies such as radiofrequency ablation, radiosurgery and, increasingly,
magnetic-resonance-guided focused ultrasonography are also often considered89. However,
DBS remains the procedure of choice for bilateral procedures owing to the increased safety
that accompanies the adjustability of the stimulation — something that lesional surgery does
not offer. Thalamic DBS has also been used for other types of tremor, including in multiple
sclerosis, for which a randomized, blinded trial found substantial clinical benefit90.
Tourette syndrome
DBS for Tourette syndrome was introduced as early as the late 1990s91. Yet, when
compared with the development of DBS in other movement disorders, propagation of this
treatment modality in Tourette syndrome has been slow. The number of patients with
Tourette syndrome who have undergone DBS thus far is estimated to be less than 300 worldwide92. One of the major problems of DBS in this patient group is the complexity of
symptoms, which consist of a variety of tics and psychiatric disturbances, such as
personality disorders, anxiety, depression, substance abuse and many others. The doubts as
to how best to treat Tourette syndrome with DBS are reflected by the uncertainty about the
target choice, which includes sub-territories of the basal ganglia and the thalamus that are
involved in motor and limbic circuitries92.
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Over the years, the efficacy of DBS for Tourette syndrome has been demonstrated in several
case series, generally with low patient numbers. According to a meta-analysis, patients with
severe symptoms benefited less than those with mild symptoms92. A randomized controlled
trial published in 2017 did not detect significant improvement of tics in individuals with
Tourette syndrome treated with anteromedial GPi stimulation during the initial blinded
phase of the study, but amelioration of tics was confirmed in the open phase of the study93.
More studies with randomized controlled designs are needed.

DBS in pain and epilepsy
Pain
Chronic pain was the first indication for chronic DBS, decades before it was considered as a
routine treatment for movement disorders94. However, after two large-scale studies in the
1980s and 1990s were stopped for various reasons (including slow patient recruitment), DBS
for pain failed to gain widespread popularity and its use was limited to a few specialized
centres world-wide95. The evaluation of the results of DBS has been intrinsically more
difficult in patients with pain than in patients with movement disorders owing to the
subjectivity of the self-assessment of pain. Although nociceptive pain generally can be well
controlled with opiate treatment, DBS of targets in the thalamus or in the cingulum is
considered for patients with severe refractory neuropathic pain95,96.
Epilepsy
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For many decades, the mainstay of surgical treatment of epilepsy has been resective surgery.
DBS has been introduced as an option for patients in whom a circumscribed focus amenable
for resection cannot be identified. Targets of stimulation include thalamic nuclei such as the
ANT or the centromedian–parafascicular complex and the hippocampus itself43,97. Early
expectations that DBS would become a central strategy in epilepsy — and possibly replace
open resective surgery — were dampened after publication of studies on DBS of the ANT,
which demonstrated efficacy but also clearly showed that the majority of patients would not
become seizure-free43,98. Closed-loop stimulation, which detects seizure activity with
sensing electrodes and delivers electric stimulation to prevent seizure propagation, is a
promising technology that needs further exploration99.

DBS for psychiatric indications
Only three DBS indications have received approval by the FDA: PD, dystonia and essential
tremor. However, the past two decades have seen rapid advances in our understanding of
putative circuits that drive the most common neurological and psychiatric disorders. The
success of DBS in modulating dysfunctional motor circuits has spurred the investigation of
DBS in other non-motor conditions, predominantly those that affect limbic circuits. Several
prospective trials have been conducted to determine whether focal disruption at discrete
anatomic targets can affect circuit-wide and network-wide changes in an effort to treat
refractory psychiatric symptoms. Although the strategy is promising, several challenges
remain. Psychiatric disorders are highly heterogeneous conditions that affect multiple
overlapping circuits. These conditions have few (if any) biomarkers to guide treatment or
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outcomes, and consensus regarding the optimal outcomes to measure is lacking. All of these
factors hamper the development of rigorously designed clinical trials. Furthermore, the
execution of surgical trials is hampered by substantial challenges surrounding recruitment, in
which factors such as heterogeneous referral patterns, a lack of consensus on the definition
of treatment resistance and an overall poor awareness and competition for patients across
ongoing trials all contribute100. Notwithstanding these challenges, the prospect of a direct
interface with pathological brain circuits in a reversible, non-ablative and image-guided
fashion continues to spur strong interest in DBS for these emerging indications.
Major depression
Major depression is a common and challenging condition that can substantially affect quality
of life, daily functioning and, ultimately, life expectancy101,102. The impact of this disorder
on individual patients has not been lost on the generations of researchers who have tried to
develop treatments with sustained antidepressant efficacy. Owing to advances in functional
imaging, evidence is now emerging that depression is driven by disturbances in key moodrelated circuits and that neuromodulation, along with other antidepressant treatments, can
contribute to reversals of circuit pathology.
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Several brain targets for DBS are currently under investigation for the treatment of
depression, including the white matter adjacent to Brodmann area 25 in the subgenual
cingulate cortex (SCC)103,104, the anterior limb of the capsula interna (ALIC), the ventral
caudate105, the lateral habenula106 and the superolateral branch of the medial forebrain
bundle (slMFB)107. To date, none of these targets have convincingly proved to be more
effective than the others, and indeed some investigators have suggested that all of these areas
represent key nodes in the same affective regulatory circuit. Interestingly, DBS to most
targets seems to be associated with sustained efficacy in individual patients, an outcome
rarely seen with other therapeutic interventions. Among all of these areas, the SCC has been
targeted in the greatest number of patients to date; DBS in this area has been linked to
treatment response rates (defined as >50% reduction in the Hamilton Depression Score
compared with baseline) of ~60–70%108. However, two industry-sponsored multicentre
randomized sham-controlled trials of either SCC or ALIC DBS in depression failed in their
primary outcome measure. In the larger of the studies, the SCC BROADEN trial, no
difference was found in response rates between the active and sham stimulation arms after 6
months, with the suggestion that total time of active stimulation (time ‘on’) was possibly
linked to improved outcomes over time109,110. On a more promising note, approximately
one-half of the patients were deemed to have responded to treatment after 18 months to 2
years of open-label stimulation. Both studies were halted after a planned futility analysis of
the data from the first patients treated. Such results underscore the challenges of large
multicentre trials in a complex, highly heterogeneous disorder such as depression.
Bipolar disorder
Patients with bipolar disorders have extreme and intense emotional states that occur at
distinct times, called mood episodes; these disorders occur less frequently than major
depression but are as debilitating and are associated with increased risk of suicide. Few
patients have been included in DBS studies of major depression, but no evidence indicates
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that DBS is less effective in bipolar depression than in unipolar depression111. DBS to the
SCC, the nucleus accumbens and slMFB seems to be associated with therapeutic effects in
bipolar disorders, but randomized, sham-controlled trials have not yet been completed112.
Obsessive–compulsive disorder
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Obsessive–compulsive disorder (OCD) is a devastating psychiatric disorder and is marked
by severe, egodystonic compulsions and anxiogenic thoughts (that is, obsessions that are
associated with time-consuming and subjectively anxiolytic behaviours). Patients often
spend hours, at the expense of their relationships, education and careers, engaged in these
thoughts and behaviours, which lead in many cases to profound disability and depression.
Although psychopharmacological and psychotherapeutic strategies are available that are
effective for many patients, up to one-third of patients do not respond to standard, guidelineconcordant care and are eligible for neuromodulation.
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In 1999, stimulation of the ALIC was proposed as an alternative to irreversible capsulotomy
for the treatment of OCD and was among the very first psychiatric indications for DBS113.
Early results led to a redefinition of the target as the area just ventral to the ALIC (the
ventral capsule and ventral striatum) and/or the nucleus accumbens114–116. In the past few
years, several groups have moved the target more posteriorly, aiming at the bed nucleus of
the stria terminalis117. As with depression, multiple targets have been proposed for the
treatment of OCD with DBS, and most are in the investigational stages at present. After
reports of improvements in OCD with STN DBS in patients with comorbid PD and OCD, a
French multicentre study explored the effects of DBS in the associative limbic part of the
STN118 and found statistically significant reduction of OCD symptoms. Furthermore,
patients with OCD treated with DBS in the region of the ventral striatum showed reduced
depression, which has led teams in North America and Europe to explore the use of DBS in
the treatment of patients with severely refractory depression119,120. In the past few years,
stimulation of the slMFB was reported to be associated with sizeable, rapid and sustained
efficacy in OCD121. Studies are ongoing in North America, Europe and elsewhere on these
applications.
Anorexia nervosa
Anorexia nervosa is a common, pervasive and highly challenging condition with one of the
highest mortalities of any psychiatric disorder. Although the physical manifestations of the
illness — namely, severe emaciation and malnourishment — are often the most obvious, a
growing body of literature has recognized the key role that limbic and emotional circuitry
have in triggering and maintaining the illness. The paucity of available treatments in patients
with refractory anorexia nervosa and the promising evidence of beneficial effects of DBS in
mood-related circuits have led to increased interest in DBS for this condition, whereby the
procedure provides a means to directly intervene in illnessdriving circuits and to address
high rates of comorbid mood disorder and anxiety. Several open-label, prospective case
series have been published investigating the role of DBS in anorexia nervosa. In the largest
series to date, 16 patients underwent SCC DBS and were monitored clinically and
radiographically for 1 year122. DBS was associated with statistically significant
improvements in measures of depression and anxiety and was also linked to sustained
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changes in cerebral glucose metabolism in key illness-related structures, as measured by
fludeoxyglucose–PET. Several months after treatment initiation, patients began to show
progressive improvements in weight that were believed to be related to improved control of
affective regulation and increased engagement with intensive treatments specific for
anorexia nervosa. These results (among others) suggest that the role for DBS in complex
conditions such as anorexia nervosa might act as adjuncts to comprehensive and
multifaceted treatment plans in highly refractory patients.

DBS in Alzheimer disease
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AD is the most common neurodegenerative condition and is marked by progressive declines
in memory and cognitive function over decades. Although the past three decades have
yielded substantial advances in our understanding of the pathological hallmarks of AD
histologically, genetically and radiographically, little therapeutic progress has been made.
Current treatment strategies aim to boost acetylcholine availability, reverse known
biochemical and metabolic disturbances or clear or prevent amyloid and tau deposition. The
ability of DBS to influence activity in key limbic circuits has driven its investigation in AD.
Initial studies reported that stimulation in hippocampal outflow pathways led to substantial
reversals in hypometabolism and stabilization of cognitive decline in some patients. Several
DBS targets for AD have been proposed, including regions immediately anterior to the
fornix, entorhinal cortex and the nucleus basalis of Meynert (NBM). Most reports to date
have been prospective and have demonstrated that DBS in memory pathways could lead to
physiological, network-wide metabolic effects and influence some aspects of memory
function. In one study, six patients with AD underwent stimulation of the NBM in a
combined 4-week double-blind, 11-month open-label study123. The authors reported that at
12 months, four of six patients responded to treatment. However, a randomized, doubleblind, phase II study of fornix DBS in mild AD did not identify a significant difference
between active and sham stimulation in the primary cognitive outcome measure at 12
months124. This study did show a statistically significant interaction between patient age
and treatment outcomes, whereby patients older than 65 years showed a trend towards
improvement in memory and cerebral metabolism at 12 months. Determination of which
patients with AD are likely to respond to DBS and which are not remains an area of active
investigation. Indeed, the variables that influence outcome are among the inherent
challenges of DBS clinical research and can include baseline neuroanatomic substrates,
surgical technique and lead placement and choice of target population and outcome
measures.

Emerging technology and strategies
The evolution of DBS and its place in the management of patients with refractory brain
conditions are intimately related to advances in technology. These advances have shaped not
only the device itself and its components (for example, with enhanced tolerability and
improvements in battery life and device size) but also the postoperative period, in which safe
coupling of DBS to high-resolution imaging can now help to shape our understanding of the
clinical effects of stimulation and the effect on brain-wide networks and circuits.
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DBS technology
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The evolution of hardware and software for spinal cord stimulation in pain management has
advanced ahead of that of DBS. Spinal cord stimulation hardware now includes surgical
paddles with 32 contacts125, expanded MRI labelling, pulse generators with built-in
accelerometers126, the ever-shrinking size of pulse generators, systems with no pulse
generator127 and special leads for stimulation of the dorsal root ganglion. The field is also
reaping the benefits of new waveforms and software strategies, such as high-frequency, highdensity and burst stimulation. DBS, on the other hand, remains a generation behind. We
must consider where we, along with industry partners, should focus our efforts to bring DBS
technology into the future. A key issue has been that where there is no competition, there is
no innovation: for two decades, a lack of competition has persisted in DBS technology,
which has suffered from stagnation as a result. Fortunately, competition now exists, which
should open the door to new ideas and developments (Box 1).
Similar to any continuous therapy, DBS requires appropriate dosing. Dosing in DBS uses
electrical stimulation parameters that control the shape and extent of the electrical field and,
within limits, the type of neural elements that are modulated. Although DBS affects a
number of electrically responsive neural elements within a given target volume, including
cell bodies, dendrites, axons and glial cells, one can simplify (for biophysical reasons) the
considerations regarding optimal dosing to the excitation of axons of different conduction
velocity and orientation, which are responsible for most of the clinical effects. The principal
goal of programming is to maximize the effect of DBS on the fibres that underlie the
beneficial effect of the therapy and avoid the recruitment of fibres related to adverse effects
(such as corticobulbar fibres that cause dysarthria) at the lowest possible energy costs to
improve device longevity.
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In current clinical practice, programming is a time-consuming, iterative, trial-and-error
process in which certain parameters are set based on experience, stimulation responses are
observed and parameters are re-adjusted on the basis of clinical outcome. This process
works reasonably well if symptoms can be reliably monitored and respond quickly to
parameter changes (for example, tremor or rigidity), enabling a time-limited ‘monopolar
review session’, whereby DBS lead contacts are individually tested for efficacy and safety.
However, many circuit disorders might not fulfil these criteria, such as dystonia, depression
or other conditions involving long-term neuroplastic changes. The resulting risk is an
inappropriate dose — often an overdose — of DBS.
In the past few years, we have seen a trend towards a translational approach to programming
based on an improved understanding of the biophysical and physiological properties of DBS
parameters. This approach has helped to partially overcome the lack of progress in DBS
development. DBS devices are now developed with consideration of the specific
neurophysiological demands of brain stimulation rather than choices being dictated by
electrical engineering and cost considerations across different pacemaker platforms. Dosefinding studies are needed that confirm an appropriate subset of the large DBS parameter
space for specific DBS indications. Predictions of suitable parameters can be derived from
assumptions about the target volume, target elements and computational models. This
method has been successfully used to model the shape and extent of the volume of brain
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tissue activated by DBS, and tools for this task are now commercially available that enable
anatomic visualization of DBS dosing. However, predictive models of the complex and
dynamic interactions between temporal pulse parameters and disordered neural
communication that underlies circuitopathies are much more difficult to develop.
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Patient registries
DBS registries are repositories of clinical and technical information that enable
identification and analysis of therapeutic effects and adverse events. An important potential
advantage of such registries is aggregation of information on these effects, which enables
detection of DBS-mediated improvements in comorbid features of an illness, among other
benefits. Furthermore, these registries permit researchers to detect changes in primary
outcomes measures, which might influence subsequent study designs128. For example, a
case report of DBS in obesity reported substantial improvements on autobiographical
memory with stimulation, despite having no effect on obesity. A trial of DBS in AD was
then designed that used the same target129. Trial registries with posted, pre-specified
outcome measures at the outset of a trial enable researchers to determine which outcomes
have been achieved and whether these outcomes need to be modified for subsequent trials.
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A central registry for therapeutic DBS trials would enable key stakeholders, including
investigators, clinicians and regulators, to access trial-specific information, including study
design, outcomes and, crucially, adverse events130. Individualized analyses would then be
possible, informed by specific disease treated, the device used, the DBS target employed and
the stimulation parameters. Given the heterogeneity of stimulation settings and anatomic
targets for some indications in the field, access to a registry would enable queries to be made
according to specific criteria. For example, querying the registry for studies that use a
specific DBS pulse width or frequency would save other researchers time and could enhance
the safety of future studies. The industry would also be able to monitor usage, benefits, risks
and adverse events to better inform device design and usability. Potential collaborations
between centres embarking on similar, or the same, trials could be more easily facilitated.

Ethical considerations
Implantation of electrodes into deep brain structures to influence their activity raises
important ethical questions, especially in new and emerging indications for DBS. This
ethical issue is related in part to the fact that DBS, although minimally invasive, is a
neurosurgical procedure that is associated with serious surgical risk, including haemorrhage
and infection. Furthermore, although DBS is standard of care in PD, it remains highly
resource intensive; DBS incurs large capital costs and necessitates a large, expert
multidisciplinary team to provide programmes for patients and troubleshoot issues. DBS
also commits patients to a lifelong implant, with subsequent battery replacements, which can
be problematic in some disorders that affect young adults. Several guidelines have been
published that attempt to systematically identify and help to address ethical issues in DBS
research and clinical practice6,131,132. Notably, these issues might differ depending on
whether established indications, such as PD, or emerging, more experimental indications,
such as depression or dementia, are considered. For the former, crucial issues might include
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resource allocation; fair distribution of and access to novel neurotechnology; and the societal
burden, financial or otherwise, of costly and resource-intensive treatments. For emerging
indications, the issues might be even more complex, including consent in vulnerable
populations, the readiness and rationale for indications for study with DBS, the role of the
medical device industry in clinical trials and the use of brain stimulation to enhance healthy,
non-pathological function. The next two decades will undoubtedly see rapid advances in our
understanding of brain circuitry, and it will be crucial that the ethical issues surrounding
those advances are addressed in parallel with the development of rigorously designed,
hypothesis-driven clinical trials.

Conclusions
DBS is a powerful tool that can be used to treat brain diseases and investigate their
underlying pathophysiology. Rapid advances in the past two decades have led to DBS
becoming a standard of care in motor circuit disorders, and several trials have also
investigated its efficacy in a number of emerging, non-motor indications. Much of the
success of DBS has been driven by preclinical, neurophysiological and computational
studies that seek to define its mechanisms and characterize its influence on neural circuitry.
Important opportunities and unmet needs in the field include technological innovation
focused on improvement of efficiency and tolerability, better integration with imaging and
other modalities and capturing the global experience through enhanced study designs and
registries. In many ways, the DBS field is still very much evolving, but with an unwavering
goal — to treat brain disease as safely and effectively as possible.
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Box 1
Major initiatives in the deep brain stimulation field
Advances in control of DBS

Europe PMC Funders Author Manuscripts

Closed-loop DBS. Stimulation can be on demand, such as the triggering of thalamic DBS
by arm movement in essential tremor or during seizure activity in epilepsy.
Alternatively, closed-loop DBS can be adaptive, with continuous modulation of DBS by
feedback such as the level of beta power in the subthalamic nucleus local field potential
in Parkinson disease.
Phase-controlled DBS. Stimulation is delivered at the specific timings (phases) that
either increase or attenuate oscillations, as required for therapy. This approach has been
piloted in thalamic DBS for tremor.
Model-based control. DBS parameters are selected and modified according to a model of
the underlying neural circuitry.
Advances in pattern of DBS
Coordinated reset DBS. This pattern of DBS is intended to disrupt locally synchronized
oscillations and change synaptic strengths so that such activity is no longer promoted.
Advances in electrode design
High-resolution electrodes. Thin-film technology and other advances are allowing the
development of multi-contact electrodes, which can even be flexible if required. The
intention is to provide better control of the stimulation field and high-resolution readouts
of neural circuit dysfunction.
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Novel IPG design
Miniaturized IPGs. IPGs that are small enough to be embedded in the skull.
Efficient rechargeable batteries. This innovation would enable increased battery life and
reduce the risk associated with surgical battery changes.
DBS, deep brain stimulation; IPG, implanted pulse generator.
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Key points
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•

Deep brain stimulation (DBS) is opening new therapeutic possibilities for
neurological and psychiatric disorders.

•

DBS is enabling neuroscientists to obtain direct measures of cellular activity
and to probe the function of neural circuits.

•

The delivery of DBS at precise locations and the wide range of stimulation
parameters available enable unprecedented temporal and spatial control of
brain circuits.

•

The mechanisms of action of DBS at the cell, molecular and systems level are
poorly understood and much work remains to be done.

•

The ethical issues presented by the application of DBS in new patient
populations and for new indications require careful consideration.
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Fig. 1. Deep brain stimulation mechanisms.

a | Neurotransmitters (inset) are released in response to stimulation, leading to calcium
waves and subsequent release of gliotransmitters. This release influences synaptic plasticity,
leading to arteriole dilation and increased regional blood flow. b | Deep brain stimulation
(DBS)-induced changes in local field potentials within the subthalamic nucleus. Activity in
the beta band is rapidly reduced with DBS at 3 V and then resumes with stimulation off.
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Table 1

Disorders currently under investigation with deep brain stimulation
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Disorder

Circuit

Parkinson disease, essential
tremor or dystonia

Motor

Major depression

Limbic

Obsessive–compulsive disorder

Tinnitus

Motor and limbic

Auditory

Tourette syndrome

Motor and limbic
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Schizophrenia — positive
symptoms

Executive
function,
cognition and
reward

Schizophrenia — negative
symptoms

Motivation,
reward, cognition
and mood

Alzheimer disease

Cognitive and
memory circuits

Pain (phantom pain,
deafferentation pain, central
pain and nociceptive pain)

Sensory systems
and interoceptive
awareness

Addiction

Reward

Postulated circuit dysfunction

•

Beta and theta oscillations

•

GPi overactivity

•

STN overactivity

•

Neuronal bursting

•

Increased activity in OFC,
SCC, amygdala and VS

•

Failure to downregulate
amygdalar activation

•

OFC hyperactivity

•

Failure of VS-mediated
thalamofrontal inhibition

Deep brain
stimulation
target(s) being
studied or that
could be
considered

Stage of study

STN, GPi, GPe,
VL thalamus,
PPN and spinal
cord

Standard of care

SCC, NAcc,
habenula and
medial forebrain
bundle

Phase III

NAcc, BNST,
ITP, ALIC and
STN

Phase II/III

•

Sensory deafferentation
Thalamocortical dysrhythmia

Auditory
pathways and
caudate nucleus

Phase I

•

GPi and CM-Pf

Phase I

Temporal cortex
and NAcc

Preclinical

NAcc, VTA and
SCC

Preclinical

Fornix,
entorhinal
cortex,
hippocampus,
cingulate,
precuneus,
frontal cortex
and nucleus
basalis

Phase II/III

Sensory
pathways,
periventricular
and
periaqueductal
areas, cingulate
and insula

Phase I/II

NAcc

Phase I/II

•

Overactive direct pathway

•

Failure of thalamocortical
inhibition

•

Thalamocortical dysrhythmia

•

Failure of saliency networks

•

Mesolimbic and mesocortical
dysfunction

•

Failure to engage anticipatory
hedonic system

•

Amyloid-β plaques throughout
the brain

•

Default mode network
dysfunction

•

Cholinergic degeneration

•

Entorhinal cortex and
hippocampal atrophy

•

Sensory deafferentation

•

Abnormal neuronal
spontaneous bursting behaviour

NAcc sensitivity to reward
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Disorder

Circuit

Anorexia nervosa

Reward and mood

Epilepsy

Various

Postulated circuit dysfunction

•

Frontoparietal disconnection

•

Parietal hypometabolism

•

Insular abnormality

•

SCC overactivity

Abnormal excitability and synchrony

Deep brain
stimulation
target(s) being
studied or that
could be
considered

Stage of study

SCC and NAcc

Phase II

CM thalamus,
anterior thalamic
nucleus,
thalamus and
seizure focus

Phase II/III

ALIC, anterior limb of the capsula interna; BNST, bed nucleus of stria terminalis; CM, centromedian; CM-Pf, CM–parafascicular; GPe, globus
pallidus externus; GPi, globus pallidus internus; ITP, inferior thalamic peduncle; NAcc, nucleus accumbens; OFC, orbitofrontal cortex; PPN,
pedunculopontine nucleus; SCC, subgenual cingulate cortex; STN, subthalamic nucleus; VL, ventral lateral; VS, ventral striatum; VTA, ventral
tegmental area. Adapted with permission from REF.1, Elsevier.
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Table 2

Proposed deep brain stimulation mechanisms
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Concept

Example evidence for

Direct inhibition of neural activity

Somatic recordings from neurons close to the
stimulating electrode

Direct excitation of neural activity

Information lesion (jamming)

Synaptic filtering

•

Biophysics of axonal
responses to electrical
stimulation

•

Antidromic and/or
postsynaptic recordings

•

Extension of the ‘excitation
mechanism’

•

Disruption of low-frequency
oscillatory patterns

•

Extension of the ‘excitation
mechanism’

•

Biophysics of high-frequency
synaptic transmission

Example evidence against
•

Antidromic and/or postsynaptic
recordings from downstream or
upstream nuclei

•

Computational modelling of
deep brain stimulation
biophysics

Refs
133,134

Stimulation-induced action potentials
intermittently or inconsistently generate
postsynaptic responses

135,136

Network interactions remain intact for highfrequency signals

20,21

Limited understanding of chronic highfrequency driving of synapses

137,17
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Table 3

use of animal models to understand brain circuits
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Indication

Animal model

Parkinson disease

MPTP in non-human
primate

Epilepsy

Pentylenetetrazol in guinea
pigs and rats

Main contribution
•

Abnormal activity detected in the STN138

•

STN lesion improves motor dysfunction36,37

•

STN high-frequency stimulation improves motor
dysfunction39

•

Lesioning of the MMT ameliorates epilepsy40

•

Electrical stimulation of the ANT ameliorates epilepsy42

Huntington disease

Transgenic rat model

•

Electrical stimulation of the GPe improves choreiform
movements139

Compulsivity-related behaviour

Polydipsia rat model

•

Electrical stimulation of the BNST effectively reduces
compulsive-like behaviour140

Depression-like behaviour

CMS rat model

•

Serotonin and BDNF are involved in the mood-related effects
of electrical stimulation of VMPFC141

•

Electrical stimulation of different brain areas has differential
influences on mood-related effects47

ANT, anterior nucleus of the thalamus; BDNF, brain-derived neurotrophic factor; BNST, bed nucleus of stria terminalis; CMS, chronic mild stress;
GPe, globus pallidus externus; MMT, mammillothalamic tract; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; STN, subthalamic nucleus;
VMPFC, ventromedial prefrontal cortex.
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